Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease
- Conditions
- Inflammatory Bowel Disease (IBD)Colorectal NeoplasmsPrimary Sclerosing Cholangitis (PSC)Colorectal Cancer
- Registration Number
- NCT01819766
- Lead Sponsor
- Exact Sciences Corporation
- Brief Summary
This study aims to determine the performance of the Exact IBD-ACRN surveillance test to detect colorectal cancer (CRC) and colorectal neoplasia in patients with inflammatory bowel disease (IBD). Patients with an IBD diagnosis for at least eight years or diagnosis of primary sclerosing cholangitis (PSC) and who are eligible for CRC screening are eligible to participate in this study. Enrolled subjects will collect a stool sample for the Exact IBD-ACRN surveillance test. Subjects must have undergone colonoscopy no more than 90 days prior to enrollment and will undergo colonoscopy or surgical intervention within 120 days of enrollment. Tissue diagnosis of CRC will be established by histopathologic examination.
- Detailed Description
This is a prospective, cross sectional, multi-center study to determine the sensitivity and specificity of the Exact IBD-ACRN surveillance test for detecting CRC alone and in combination with high grade dysplasia (HGD) and low grade dysplasia (LGD) associated with IBD and advanced adenoma in IBD patients with disease duration greater than 8 years or PSC diagnosis. Enrolled subjects will provide a single stool sample for the Exact IBD-ACRN surveillance test, no sooner than 7 days following their most recent pre-enrollment colonoscopy, within 30 days of enrollment and prior to initiating bowel prep for either the post-enrollment colonoscopy (surveillance or repeat), or surgical intervention. Stool samples will be tested using the Exact IBD-ACRN surveillance test and results compared to the colonoscopy and corresponding diagnostic histopathology results from biopsied, and any subsequently excised, lesions to establish sensitivity and specificity of the Exact IBD-ACRN surveillance test. All post-enrollment colonoscopies or surgical interventions must be performed within 60 days of enrollment.
The primary objective of this study is to determine the sensitivity and specificity of the Exact IBD-ACRN surveillance test for CRC in IBD patients with disease duration of at least eight years or diagnosis of PSC. Tissue diagnosis of CRC will be established by histopathology examination. The secondary objective is to determine the sensitivity and specificity of the Exact IBD-ACRN surveillance test to detect ACRN in IBD patients with disease duration of at least eight years or diagnosis of PSC.
Enrollment will continue until at least 35 CRC; 15 HGD and 315 negative subject samples have been obtained. There is no specific recruitment goal for IBD associated LGD or LGD associated with advanced adenoma (AA).
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 440
- Male or female 18-84 years of age, inclusive.
- Diagnosis of IBD or a diagnosis of PSC with IBD prior to enrollment date of this study.
- Must be a candidate for a surveillance colonoscopy, with the intention of CRC/dysplasia surveillance, or a candidate for surgical intervention based on prior histological confirmation of HGD or CRC.
- Written informed consent document signed and dated by the subject or legally acceptable representative.
- Any condition that in the opinion of the investigator should preclude participation in the study.
- A history of aerodigestive tract cancer.
- Prior colorectal resection, except ileocolic resection in Crohn's disease patients.
- IBD limited only to the rectum and without a concurrent PSC diagnosis.
- Subject has participated in any clinical study within the previous 30 days wherein an investigational compound or device was, or may be, introduced into the subject.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Sensitivity and Specificity of the Exact Sciences IBD-ACRN screening test for CRC. 9 months With comparison to the colonoscopy results and histopathologic diagnosis of all lesions discovered during colonoscopy and either biopsied or removed during or subsequently removed after colonoscopy.
- Secondary Outcome Measures
Name Time Method Determine Sensitivity and Specificity of the Exact Sciences IBD-ACRN screening test for CRC and HGD. 9 months Subjects with colonoscopic findings of CRC and/or high grade dysplasia (HGD) will be considered to have a positive outcome for composite CRC-HGD sensitivity calculations. Subjects with negative colonoscopic findings will be considered to have a negative outcome.
Trial Locations
- Locations (26)
Mount Sinai School of Medicine
🇺🇸New York, New York, United States
UC San Diego Medical Center
🇺🇸La Jolla, California, United States
Medical Research Associates of New York
🇺🇸New York, New York, United States
Blue Ridge Medical Research
🇺🇸Lynchburg, Virginia, United States
NorthShore University Health System
🇺🇸Evanston, Illinois, United States
MGG Group, Co. Inc./Chevy Chase Clinical Research
🇺🇸Chevy Chase, Maryland, United States
Detroit Clinical Research Center, PC
🇺🇸Farmington Hills, Michigan, United States
Gastroenterology Associates, LLC
🇺🇸Baton Rouge, Louisiana, United States
Center for Digestive and Liver Diseases, Inc
🇺🇸Mexico, Missouri, United States
Asheville Gastroeneterology Associates
🇺🇸Asheville, North Carolina, United States
Houston Methodist Hospital
🇺🇸Houston, Texas, United States
Advanced Research Institute
🇺🇸Logan, Utah, United States
Winnipeg Regional Health Authority-Health Sciences
🇨🇦Winnipeg, Manitoba, Canada
University of Wisconsin Hospital and Clinics
🇺🇸Madison, Wisconsin, United States
University of Calgary
🇨🇦Calgary, Alberta, Canada
Mayo Clinic Arizona
🇺🇸Phoenix, Arizona, United States
University of Miami
🇺🇸Miami, Florida, United States
Rush University Medical Center
🇺🇸Chicago, Illinois, United States
University of Chicago Medicine
🇺🇸Chicago, Illinois, United States
Massachusetts General Hospital
🇺🇸Boston, Massachusetts, United States
Boston Medical Center
🇺🇸Boston, Massachusetts, United States
Univeristy of North Carolina
🇺🇸Chapel Hill, North Carolina, United States
Cleveland Clinic
🇺🇸Cleveland, Ohio, United States
Vanderbilt University Medical Center
🇺🇸Nashville, Tennessee, United States
Mayo Clinic
🇺🇸Rochester, Minnesota, United States
Wisconsin Center for Advanced Research
🇺🇸Milwaukee, Wisconsin, United States